Sutro Biopharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Sutro Biopharma şirketinin kazançlarının yıllık 0.7% oranında düşmesi, yıllık gelirinin ise yıllık 27.4% oranında artması bekleniyor. EPS'nin yıllık 8.2% oranında büyümesi bekleniyor.

Anahtar bilgiler

-0.7%

Kazanç büyüme oranı

8.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	27.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:S09 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	51	-313	-210	-298	9
12/31/2025	49	-297	-236	-294	11
12/31/2024	59	-224	-192	-206	11
9/30/2024	161	-124	-109	-106	N/A
6/30/2024	169	-124	-78	-75	N/A
3/31/2024	154	-115	-119	-115	N/A
12/31/2023	154	-107	-116	-112	N/A
9/30/2023	49	-172	-156	-150	N/A
6/30/2023	57	-143	-57	-50	N/A
3/31/2023	75	-130	-29	-22	N/A
12/31/2022	68	-119	-4	4	N/A
9/30/2022	70	-123	-1	6	N/A
6/30/2022	53	-134	-96	-84	N/A
3/31/2022	53	-114	-101	-87	N/A
12/31/2021	62	-106	-97	-82	N/A
9/30/2021	60	-127	-93	-79	N/A
6/30/2021	69	-79	-85	-72	N/A
3/31/2021	50	-43	-88	-79	N/A
12/31/2020	43	-32	-75	-68	N/A
9/30/2020	46	13	-70	-62	N/A
6/30/2020	40	-17	-66	-61	N/A
3/31/2020	41	-61	-68	-64	N/A
12/31/2019	43	-56	-69	-65	N/A
9/30/2019	51	-42	-60	-58	N/A
6/30/2019	46	-40	4	6	N/A
3/31/2019	41	-38	6	8	N/A
12/31/2018	38	-35	11	13	N/A
9/30/2018	23	-49	12	14	N/A
6/30/2018	33	-40	N/A	-36	N/A
3/31/2018	42	-30	N/A	-37	N/A
12/31/2017	52	-20	N/A	-37	N/A
12/31/2016	60	N/A	N/A	-13	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: S09 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: S09 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: S09 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: S09 şirketinin gelirinin (yıllık 27.4% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: S09 şirketinin gelirinin (yıllık 27.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: S09 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Sutro Biopharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2025

Recent updates

Third quarter 2024 earnings released: US$0.59 loss per share (vs US$0.81 loss in 3Q 2023)

Sutro Biopharma, Inc. Announces Initiation of the Registration-Enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-Term Pipeline At Research Forum

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO2024

Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Second quarter 2024 earnings released: US$0.59 loss per share (vs US$0.64 loss in 2Q 2023)

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

First quarter 2024 earnings released: US$0.95 loss per share (vs US$0.85 loss in 1Q 2023)

Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Full year 2023 earnings released: US$1.78 loss per share (vs US$2.35 loss in FY 2022)

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.37 loss in 3Q 2022)

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold €67k worth of stock

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.55 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.84 loss in 1Q 2022)

Full year 2022 earnings released: US$2.35 loss per share (vs US$2.29 loss in FY 2021)

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Sutro Biopharma, Inc. Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.67 loss in 3Q 2021)

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.13 loss in 2Q 2021)

High number of new directors

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

High number of new directors

First quarter 2022 earnings released: US$0.84 loss per share (vs US$0.66 loss in 1Q 2021)

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022

Sutro Biopharma, Inc. Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

CEO & Director recently bought €71k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

High number of new directors

Sutro Biopharma, Inc. Announces Company Kol Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program Stro-002 for Treatment of Advanced Ovarian Cancer

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present At American Society of Hematology Annual Meeting 2021

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$0.47 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$1.00 profit in 2Q 2020)

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to Be Presented At ASCO 2021

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$6.61 loss per share (vs US$0.84 loss in 1Q 2020)

Full year 2020 earnings released: US$0.99 loss per share (vs US$2.43 loss in FY 2019)

Investor sentiment deteriorated over the past week

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

New 90-day high: €21.00

Investor sentiment improved over the past week

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

Market bids up stock over the past week

New 90-day high: €18.60

Sutro Biopharma Announces Appointment of Jon M. Wigginton to Board of Directors

Sutro Biopharma, Inc. Appoints Annie Chang as Head of Investor Relations

New 90-day high: €14.30

Market bids up stock over the past week

Revenue beats expectations

Third quarter 2020 earnings released: EPS US$0.46

New 90-day high: €11.10

New 90-day high - €10.00

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin